Lisata Therapeutics, Inc. (8NE)
XSTU 
Summary
8NE Chart
Lisata adds biopharma finance veteran Jeffrey Farrow to board
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to eight members.
Lisata Therapeutics wins new US patent for pancreatic cancer drug
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said. The US Patent and Trademark Office issued the Method of Use patent titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors.
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an experimental antibody that blocks a protein called ANGPTL4, which helps fat tissue work properly, with the goal of lowering triglycerides and improving how the body handles fat.
Lisata Therapeutics, Inc. (8NE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lisata Therapeutics, Inc. ever had a stock split?
Lisata Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David J. Mazzo CEO | XSTU Exchange | US1280583022 ISIN |
| US Country | 21 Employees | - Last Dividend | 15 Sep 2022 Last Split | 1 Mar 1999 IPO Date |
Overview
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for the treatment of solid tumors and various diseases. Founded in 1980, the company has been at the forefront of research and development in oncology and other critical areas of medicine. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics aims to deliver breakthrough treatments that can significantly improve patient outcomes. With a focus on identifying and advancing promising drug candidates, the company is committed to addressing some of the most challenging medical conditions faced today.
Products and Services
- LSTA1
This product candidate is currently in Phase 2a and 2b clinical studies for the treatment of solid tumors. It shows particular promise in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) when used in combination with various anti-cancer regimens. LSTA1 represents Lisata Therapeutics' dedication to combating one of the most aggressive and hard-to-treat cancers.
- XOWNA
XOWNA is another innovative treatment under development, currently undergoing a Phase IIa clinical trial. It is designed for the treatment of coronary microvascular dysfunction, a condition that affects the small vessels supplying blood to the heart muscle. This represents a significant advancement in addressing a key area of unmet medical need in cardiovascular disease.
- CD34+ Cell Therapy
Targeting chronic kidney disease, this CD34+ cell therapy is among Lisata Therapeutics' novel approaches to treating chronic conditions with high unmet clinical needs. By leveraging the potential of CD34+ cells, this therapy aims to offer new hope to patients suffering from chronic kidney disease, showcasing the company's commitment to innovating in areas where traditional treatments have fallen short.
Contact Information
